Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 13/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21527698 | 1.00 | PYGL (0.38) | PYGLCYP2C9KEAP1CTSSCTSK | |
| SCHEMBL2395128 | 0.87 | CTSK (0.49) | PYGLCYP2C9CTSSCTSK | |
| SCHEMBL2418915 | 0.87 | CTSK (0.49) | PYGLCYP2C9CTSSCTSK | |
| SCHEMBL8222608 | 0.87 | CTSK (0.49) | PYGLCYP2C9CTSSCTSK | |
| SCHEMBL14453090 | 0.87 | CTSK (0.49) | PYGLCYP2C9CTSSCTSK | |
| SCHEMBL14038647 | 0.87 | CTSK (0.49) | PYGLCYP2C9CTSSCTSK | |
| SCHEMBL14039301 | 0.87 | CTSK (0.49) | PYGLCYP2C9CTSSCTSK | |
| SCHEMBL6476152 | 0.87 | CTSK (0.49) | PYGLCYP2C9CTSSCTSK | |
| SCHEMBL6640994 | 0.87 | CTSK (0.49) | PYGLCYP2C9CTSSCTSK | |
| SCHEMBL12943346 | 0.85 | CTSK (0.33) | KEAP1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121537485-A | Cyclohexapeptide and preparation method and application thereof | 未来多肽生物科技(烟台)有限公司 | 2026-02-17 | — | — | CN | disclosed |
| CN-120248044-A | Cyclohexapeptide and preparation method and application thereof | 陕西未来多肽生物科技有限公司 | 2025-07-04 | — | — | CN | disclosed |
| CN-119591674-A | Cyclohexapeptide and preparation method and application thereof | 陕西未来多肽生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-07 | — | — | US | disclosed |
| EP-3239153-B1 | 9-(1H-IMIDAZOL-5-YL)-1,11-DIHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HCV NS5A | GILEAD PHARMASSET LLC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2014-10-23 | — | — | US | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| WO-2013173488-A1 | ANTIVIRAL COMPOUNDS INHIBITORS OF HCV NS5B | GILEAD SCIENCES, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2013-11-21 | — | — | US | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PYGL 2026/4885CYP2C9 3296/4885KEAP1 2326/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PYGL 88/4885CYP2C9 3780/4885KEAP1 206/4885 |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PYGL 844/4885CYP2C9 3743/4885KEAP1 3086/4885 |
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PYGL 88/4885CYP2C9 3780/4885KEAP1 206/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PYGL 88/4885CYP2C9 3780/4885KEAP1 206/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PYGL 2026/4885CYP2C9 3296/4885KEAP1 2326/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | PYGL 844/4885CYP2C9 3743/4885KEAP1 3086/4885 |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PYGL 844/4885CYP2C9 3743/4885KEAP1 3086/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PYGL 88/4885CYP2C9 3780/4885KEAP1 206/4885 |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PYGL 844/4885CYP2C9 3743/4885KEAP1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.